Efficacy and safety of seladelpar vs placebo in patients with primary biliary cholangitis and metabolic syndrome in the pivotal phase 3 RESPONSE study

M J Mayo, E J Lawitz, A M Villamil, E Janczewska, P Andreone, M-C Londoño, A Villagrasa, J Wiegand, S Proehl, L Wang, D B Crittenden, C L Bowlus · Zeitschrift für Gastroenterologie · 2026 · Heft 08 · S. e364